Piper Sandler analyst Edward A. Tenthoff assumed coverage of CytomX Therapeutics (CTMX) with an Overweight rating with a price target of $2.50, down from $3.25. The firm notes CytomX is enrolling the 7th cohort in the Phase I dose-escalation study of CX-2051 in metastatic colorectal cancer with initial data in Q2 2025. Clean safety data will validate this masked EpCAM ADC with any efficacy signal including stable disease a positive in lateline CRC patients, adds Piper. CytomX is also conducting Phase I dose-escalation of Probody masked interferon-alpha2b CX-801 i metastatic melanoma with initial PD data in the second half of 2025 and efficacy data in 2026.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics participates in a conference call with JPMorgan
- Biotech Alert: Searches spiking for these stocks today
- CytomX Therapeutics Faces Critical Challenges in Product Development and Market Viability
- CytomX Therapeutics’ Earnings Call Highlights Progress and Challenges
- Cautious Outlook for CytomX Therapeutics Amid Pipeline Challenges and Strategic Setbacks
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue